- Home
- OPCH vs IMVT Comparison
OPCH vs IMVT Comparison
Compare OPCH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | IMVT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.3B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OPCH | IMVT |
|---|---|---|
| Price | $30.85 | $26.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $37.44 | $30.78 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $4,998,202,000.00 | N/A |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | $24.55 | ★ N/A |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $24.24 | $12.72 |
| 52 Week High | $36.80 | $29.25 |
Technical Indicators
Market Signals| Indicator | OPCH | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 51.40 |
| Support Level | $27.04 | $24.63 |
| Resistance Level | $31.14 | $27.71 |
| Average True Range (ATR) | 1.20 | 1.07 |
| MACD | -0.51 | 0.01 |
| Stochastic Oscillator | 18.46 | 40.02 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.